Liminal BioSciences

$4.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-3.03%) Today

-$0.02 (-0.42%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell LMNL and other stocks, options, and ETFs commission-free!

About LMNL

Liminal BioSciences Inc. Common Shares, also called Liminal BioSciences, is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada. The listed name for LMNL is Liminal BioSciences Inc. Common Shares.

CEO

Bruce Philip Pritchard

Employees

300

Headquarters

Laval, Québec

Founded

1994

Market Cap

155.87M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

707.45K

High Today

$4.90

Low Today

$4.57

Open Price

$4.83

Volume

395.84K

52 Week High

$31.45

52 Week Low

$3.51

LMNL Earnings

-$0.74

-$0.49

-$0.25

$0.00

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 19, After Hours